Best radiographic response for patients with mRCC and brain metastasis treated with ipilimumab and nivolumab among all patients, those treated in the first line setting and those treated in the second line or later setting
| Variable | All patients (n=19) | First line (n=13) | Second line or later (n=6) |
| Best overall response, no. (%) | |||
| Complete response | 0 | 0 | 0 |
| Partial response | 8 (42) | 5 (38.5) | 3 (50) |
| Stable disease | 6 (32) | 5 (38.5) | 1 (17) |
| Progressive disease | 4 (21) | 2 (15) | 2 (33) |
| Not evaluable | 1 (5) | 1 (8) | 0 |
mRCC, metastatic renal cell carcinoma.